KLRS
Kalaris Therapeutics, Inc.
2.60$
-3.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -98.7% | +4,224.7% | -9.1% | -98.1% | +4,717.0% | -13.0% | -9.9% | -12.6% | +50.0% | -9.8% | -9.3% | |
| – | -98.5% | +4,144.9% | -8.2% | -98.3% | +5,421.5% | -13.8% | -10.3% | -14.7% | +52.0% | -17.5% | -2.2% | |
| – | -96.7% | +2,615.0% | +21.7% | -98.2% | +6,083.4% | -14.6% | -12.4% | -52.1% | +131.3% | -64.9% | +25.4% | |
| – | -98.5% | +4,334.5% | -7.8% | -98.5% | +6,083.4% | -14.6% | -12.4% | -12.9% | +53.2% | -17.6% | -3.8% | |
| – | – | – | -47.0% | – | – | – | – | – | – | – | – | |
| – | -8.7% | -51.0% | -54.9% | +758.7% | -94.3% | +648.6% | +1.3% | -1.0% | +9.2% | -3.9% | +1.5% | |
| – | -88.1% | +94.2% | -69.2% | +483.6% | -61.9% | +36.3% | +7.1% | -20.7% | +60.2% | -16.8% | +8.2% | |
| – | – | – | -70.9% | +1,287.3% | – | – | – | – | -16.0% | +0.3% | +9.5% | |
| – | -39.8% | -67.6% | -85.6% | +1,925.5% | -88.9% | +861.1% | +55.0% | -86.6% | +159.3% | -29.4% | +24.2% | |
| – | -123.0% | – | -0.1% | -174.3% | – | -43.6% | -16.8% | -21.2% | +88.3% | -13.0% | -15.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.5% | +0.0% | +0.0% | +0.8% | -19.3% | +361.4% | +0.0% | +22.5% | +3.6% | +0.3% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.